This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/kegg-compound/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/bindingdb/
n13http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/pubchem-compound/
n28http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/drugbank/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n31http://www.rxlist.com/cgi/generic/
n16http://linked.opendata.cz/resource/drugbank/patent/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/chebi/
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n26http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00701/identifier/pharmgkb/
n30http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00701
rdf:type
n3:Drug
n3:description
Amprenavir is a protease inhibitor used to treat HIV infection.
n3:group
approved
n3:halfLife
7.1-10.6 hours
n3:indication
For the treatment of HIV-1 infection in combination with other antiretroviral agents.
n3:manufacturer
n8:271B493B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00701 n25:DB00701
dcterms:title
Amprenavir
adms:identifier
n15:DB00701 n17:2684 n18:58532 n19:PA448422 n20:65016 n21:C08086 n22:D00894 n23:Amprenavir n24:577 n29:46507537
n3:mechanismOfAction
Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
n3:packager
n8:271B493A-363D-11E5-9242-09173F13E4C5
n3:patent
n16:6730679 n16:5585397
n3:synonym
Amprénavir Amprenavirum Amprenavir Agenerase (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate
n12:hasAHFSCode
n13:08-18-08-08
n3:foodInteraction
Take with or without food, however avoid lipid-rich meals. Avoid alcohol, especially with the oral solution since it contains propylene glycol which competes with alcohol for alcohol dehydrogenase metabolism. Vitamin E increases amprenavir bioavailability.
n3:proteinBinding
Very high (90%). Amprenavir has the highest affinity for alpha(1)-acid glycoprotein.
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Amprenavir.htm
n27:hasConcept
n28:M0250495
foaf:page
n10:amprenavir.html n26:age1526.shtml n31:ampren.htm
n3:IUPAC-Name
n4:271B4942-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4948-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4947-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4944-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4945-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4946-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4940-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4941-363D-11E5-9242-09173F13E4C5 n4:271B493E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B493F-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n30:J05AE05
n3:H-Bond-Acceptor-Count
n4:271B494E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B494F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4949-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B494A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B494C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B494B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B494D-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (T<sub>max</sub>) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established.
n3:affectedOrganism
Human Immunodeficiency Virus
n3:casRegistryNumber
161814-49-9
n3:category
n3:containedIn
n7:271B493C-363D-11E5-9242-09173F13E4C5 n7:271B493D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4954-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4956-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4957-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4953-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4952-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4955-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4943-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4950-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4951-363D-11E5-9242-09173F13E4C5